AVLN · Avalyn Pharma Inc.

Current Thesis

Since the last note the tape has taken back part of the August unwind with no company datapoint in either direction. The 2026-09-04 close is $37.39, against the 2026-08-28 close of $34.69 and the 2026-08-14 close of $39.25. RSI(14) reads 46.3, versus 89.2 at that 2026-08-14 close. The three-month price change stands at +33.3% as of 2026-09-04. StockTitan's news log for the ticker showed no SEC filing and no analyst action dated in September as of 2026-09-05; the last dated company communication remains the 2026-08-24 announcement of two ERS poster presentations, and the last dated sell-side action remains Morgan Stanley's 2026-08-13 Overweight maintenance with the target raised to $57 from $53.

The substance an investor is buying has not moved: a fully enrolled 398-patient Phase 2b (MIST, AP01 inhaled pirfenidone, 52 weeks, forced vital capacity primary endpoint), $413.5M of cash and marketable securities at 2026-06-30 with runway guided "into 2029," a published target bracket of $51 to $80, and a topline the company guides to 2H 2027. The narrative is maturing — the inhaled-antifibrotic story is well known since the 2026-04-30 listing and the May–June coverage build-out, no new sell-side action has been dated since 2026-08-13, and the two events on the calendar inside 30 days are a congress poster session carrying no efficacy data and, beyond it, a supply event.

One mechanical point, stated as inference rather than a company datapoint: RSI(14) is lower on 2026-09-04 (46.3) than on 2026-08-28 (50.4) while the close is higher, because the 14-session window has rolled the mid-August advance out of its numerator and now spans the 2026-08-14 peak and the decline that followed. It is an arithmetic property of the window, and it means the oscillator is not confirming the recovery in price.

Bullish and bearish views on Avalyn Pharma Inc.

The model's bull view on Avalyn Pharma Inc. (AVLN), in brief: Enrollment risk is closed and the clock is fixed. The bear view: Fourteen months of empty efficacy calendar. Both cases follow in full.

Bull Case

• Enrollment risk is closed and the clock is fixed. MIST randomized 398 patients against a 375 target across three treatment cohorts; 52-week study, primary endpoint change in FVC, topline anticipated 2H 2027 (Q2 2026 results release, 2026-08-12).
• Funded through the readout on the stated plan. $413.5M in cash, cash equivalents and marketable securities at 2026-06-30, including $316.6M net proceeds from the May 2026 IPO close, with runway guided "into 2029" — spanning both MIST topline (2H 2027) and AP02's AURA Phase 2 result (late 2027).
• Every published target sits above the market. Morgan Stanley $57 (2026-08-13), Guggenheim Buy $80, Jefferies Buy $52, Evercore ISI Outperform $51; MarketBeat's compiled consensus was $59.00 as of 2026-08-15, against the 2026-09-04 close of $37.39.
• The August drawdown found a floor above the pre-print range. The 2026-08-28 close of $34.69 was not undercut into 2026-09-04, and the three-month price change is higher on 2026-09-04 (+33.3%) than it was on 2026-08-28 (+30.1%). Both are tape observables, not company disclosures.
• The pipeline is not one asset. AP02 (inhaled nintedanib) is enrolling in Phase 2 AURA with results expected late 2027; AP03, a pirfenidone/nintedanib combination, is targeted to enter Phase 1 by end-2026 (2026-08-12 release).

Bear Case

• Fourteen months of empty efficacy calendar. No company-guided efficacy readout exists between 2026-09-06 and 2H 2027. Positioning, sentiment and small-cap biotech risk appetite carry the price across that span.
• The 2026-09-07 posters cannot move the fundamental case. Session #246 (poster PA3014, 08:00–09:30 GMT) is a patient-preference survey on IPF trial participation; session #378 (poster PA4377, 12:30–14:00 GMT) is in silico modeling of nebulized AP01 aerosol distribution. Neither reports FVC or clinical outcomes.
• Burn is scaling ahead of the story. Q2 2026 R&D $24.7M against $17.9M a year earlier; G&A $6.6M against $3.9M; net loss $28.9M against $20.2M. Reported EPS of $(0.65) missed the $(0.53) consensus on 2026-08-12.
• Supply arrives before data. The IPO lock-up runs 180 days from the 2026-04-29 pricing, placing expiry near 2026-10-26 — the first dated release of pre-IPO stock into a float that has never absorbed selling, with the market roughly double the $18.00 IPO price.
• The valuation is carried entirely by a forward event. StockTitan's quote page put market capitalization near $1.7B on 2026-09-05 against $413.5M of cash at 2026-06-30 and no product revenue.

Setup & Price Structure

The 2026-09-04 close of $37.39 sits inside the band the name has traded since the Q2 print: the 2026-08-14 close of $39.25 above, the 2026-08-28 close of $34.69 below. RSI(14) at 46.3 is mid-range and, as noted above, is not confirming the price recovery. The listing dates from 2026-04-30, roughly ninety sessions of history, so no 200-day average exists for this name and any long-horizon technical reference is unavailable rather than merely unfavourable.

The only structural level below the current band that has a non-technical origin is the $18.00 IPO price from 2026-04-29. Between that and the August band there is no volume shelf built over months, because the shares have not existed for months.

On crowding and positioning, the observables are these: no sell-side initiation, target revision or estimate change has been dated since 2026-08-13, leaving the $51–$80 bracket static while the price moved; no SEC filing appeared for the ticker in September through 2026-09-05; and the first dated supply event, the ~2026-10-26 lock-up expiry, is roughly fifty days out and is not yet visible in any Form 144 or resale registration. Those are the facts on the record — the inference that a static target bracket implies a thinning marginal bid is a reading of them, not a measurement.

Catalyst Calendar (next 30 days)

• ~2026-10-26 (est.) — IPO lock-up expiry, 180 days from the 2026-04-29 pricing. Outside the 30-day window but the first dated supply event on the calendar.

Nothing else is scheduled inside 30 days. Q3 2026 results are unscheduled; the 2026-08-12 Q2 cadence points to mid-November.

Elapsed catalysts

• 2026-09-07 — Both Avalyn ERS posters presented in Barcelona: session #246 / PA3014 (08:00–09:30 GMT) on IPF patient perspectives, and session #378 / PA4377 (12:30–14:00 GMT) on in silico AP01 aerosol modeling. Announced 2026-08-24. (passed 4d ago)
• 2026-09-09 — ERS International Congress 2026 closes. A flat or lower tape through the congress week dates the point at which company presence stopped supporting the bid. (passed 2d ago)

What Would Change Our Mind

The frame breaks on supply, not on data, because there is no data before 2H 2027. A registered follow-on, shelf takedown or a cluster of Form 144 filings dated into the ~2026-10-26 lock-up expiry would convert a scarce float into visible supply at roughly twice the $18.00 IPO price, and would do so fourteen months before any FVC number exists to defend the valuation. On price, a weekly close below $30 puts the entire post-Q2 re-rating band behind the tape, with the $18.00 IPO price the next reference of any origin below it.

The reverse also has a shape. A dated sell-side initiation or target revision after 2026-08-13, or a Q3 release in mid-November that holds "into 2029" runway language against an R&D run-rate that reached $24.7M in Q2, would restore a flow argument that currently has nothing dated behind it. A congress week that comes and goes — 2026-09-07 posters presented, 2026-09-09 close — with the price back below the 2026-08-28 close of $34.69 would date the exhaustion of company-presence support directly.

Correlation Notes

No theme cluster in the current registry carries this name, so the thesis leans on single-name flow rather than a group move, and nothing here should be read as a sector call. With no product revenue, the correlation that matters is to small-cap clinical biotech risk appetite and to the IPF/progressive-pulmonary-fibrosis read-across set — a competing Phase 3 hitting an FVC primary endpoint in PPF, or a label expansion for an incumbent oral antifibrotic, would compress the opportunity Avalyn is being valued against before MIST reports.

Any statistical correlation estimate on this ticker is built on about ninety sessions since the 2026-04-30 listing, of which the meaningful ones cluster around the 2026-08-12 print. That sample is too small to support a claim about beta or about how the name behaves in a biotech drawdown.